Wirtschaftsdaten und Aktien Chat WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: DiMarco

Bin kein Profi, schaut aber nicht schlecht außi. 🖐🌞 23.05.2024: Data in Published Abstract and Upcoming Oral Presentation Strongly Support Ongoing TILVANCE-301 Phase 3 Trial SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online. Clinical Data in Frontline Advanced Melanoma (Cohort 1A in IOV-COM-202 Trial) Positive results from Cohort 1A in the IOV-COM-202 trial were published in an abstract1 and will be highlighted in an upcoming oral presentation at ASCO. Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy. These results strongly support the ongoing Phase 3 TILVANCE-301 clinical trial. ASCO Oral Presentation Highlights A recent data cut included 23 patients with a median follow up of 21.7 months.2 Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1. All evaluable patients demonstrated regression of their target lesions. Nearly all responses remained ongoing. The duration of response was 12+ months for 8 responders (53.3%) and 6+ months for 11 responders (73.3%). As a one-time treatment, lifileucel’s safety profile was differentiated from continuous ICI combination regimens. Treatment-emergent adverse events were consistent with the underlying disease and known safety profiles of pembrolizumab monotherapy, nonmyeloablative lymphodepletion, and interleukin-2. Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, “The compelling response rates, including a 30.4% complete response rate, and depth and durability of responses for lifileucel in combination with pembrolizumab strongly support our strategy in frontline advanced melanoma. Expanding TIL cell therapy into earlier treatment settings is a top priority for Iovance. The positive data are highly encouraging for the anticipated ORR results in our ongoing TILVANCE-301 trial. A planned early interim analysis of ORR, a dual primary endpoint in TILVANCE-301, may support an accelerated approval in the frontline setting, with full approval supported by progression free survival.”

https://youtube.com/shorts/fQKvtlS3xs8?si=WYhjVjv4HWH9lRVy

Guten Morgen🖐🌞

Guten Morgen ☀️ zusammen

... Der markbreite S&P 500 büßte 0,7 Prozent auf 5.267,84 Punkte ein. ...

https://www.deraktionaer.de/artikel/indizes/schluss-wall-street-nvidia-top-moderna-erneut-im-plus-boeing-tesla-intel-bitcoin-unter-druck-20358108.html

20:36 Uhr, focus-online ... setzt die Insel (Taiwan) ganz wesentlich auf die sogenannte „Stachelschwein“-Strategie: Kleinere, aber hochwirksame Waffen sollen eine Invasion für Peking äußert kostspielig machen. ...

... Die Militärübung fällt in Zeit des politischen Umbruchs in Taiwan: Zu Beginn der Woche war der neue taiwanische Präsident in sein Amt eingeführt worden, den Peking als "gefährlichen Separatisten" bezeichnet. ...

https://www.n-tv.de/politik/Peking-droht-Unabhaengigkeitsbefuerwortern-in-Taiwan-mit-Blutvergiessen-article24961335.html (Politik)

https://www.n-tv.de/wirtschaft/Schokolade-zu-teuer-Mondelez-muss-Millionenstrafe-zahlen-article24961537.html 🍫🍫🍫👊

💡Die Wachstumsstory von Gerresheimer dürfte mit dem Zukauf ab 2025 an zusätzlicher Dynamik gewinnen. Zudem dürften sich die Margen mit der Akquisition weiter verbessern. ...

... Im ersten Quartal ächzte Gerresheimer noch unter dem Abbau von Lagerbeständen ...

Kursziele: 128 Euro

... Zuletzt hätten die Papiere des Verpackungsspezialisten einen schweren Stand gehabt angesichts schlechter Botschaften von Schott Pharma und Stevanato. ...

... Die am Morgen angekündigte Übernahme der Bormioli Pharma Gruppe, die sich zuletzt im Besitz der Private-Equity-Gesellschaft Triton befunden hat, findet am Kapitalmarkt regen Anklang. ...

https://www.deraktionaer.de/artikel/pharma-biotech/gerresheimer-befreiungsschlag-mit-uebernahme-aktie-startet-durch-20358029.html